Sodium-glucose cotransporter 2 (SGLT2) inhibitors (inhibiting the reabsorption of glucose in the proximal tubule, resulting in the promotion of urinary glucose excretion and improvement in glycemic control) were originally developed as drugs for DM. This evidence concerns the gene SLC5A2 and diabetes mellitus.